Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
10 Novembre 2008 - 12:05PM
PR Newswire (US)
MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Memory
Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that six
abstracts related to its clinical and preclinical programs have
been accepted for poster presentations at the 38th Annual Meeting
of the Society for Neuroscience in Washington, D.C. from November
15-19, 2008. The abstracts include additional preclinical data for
R3487/MEM 3454, the Company's lead nicotinic alpha-7 receptor
agonist currently in Phase 2 development for both Alzheimer's
disease and cognitive impairment associated the schizophrenia
(CIAS), new preclinical data for the Company's lead 5-HT(6)
receptor antagonist, MEM 68626, and data from its collaboration
with Amgen focused on the development of PDE10 inhibitors. "We
continue to advance the development of novel therapies for the
treatment of cognitive disorders and look forward to reporting on
the new data emerging from our key programs," stated David A. Lowe,
Ph.D., Chief Scientific Officer of Memory Pharmaceuticals. "We and
our partner Roche are evaluating R3487/MEM 3454 as a treatment for
both Alzheimer's disease and CIAS, and the preclinical data for
R3487/MEM 3454 adds to the growing body of evidence suggesting the
compound enhances cognition. In addition, MEM 68626 continues to
demonstrate efficacy in multiple models of memory, including new
findings of enhanced performance in a spatial working memory task.
Furthermore, we continue to progress our program focused on
advancing PDE10 inhibitors for potential clinical development." The
following abstracts from Company scientists and collaborators were
accepted for poster presentations at the meeting: -- "The alpha-7
receptor partial agonist MEM 3454 increases dopamine and
acetylcholine efflux in rat medial prefrontal cortex and
hippocampus, alone and augments the effect of atypical
antipsychotic drugs" Poster Session 874 Wednesday, November 19,
2008 1:00 p.m. - 5:00 p.m. EST -- "Serotonin 5-HT(6) receptor
antagonists modulate episodic, spatial and working memory,
highlighting a potential therapeutic role in alleviating deficits
associated with mild cognitive impairment and Alzheimer's disease"
Poster Session 685 Tuesday, November 18, 2008 1:00 p.m. - 5:00 p.m.
EST -- "Identification and characterization of a novel small
molecule inhibitor for phosphodiesterase 10A as a potential
PET-tracer using LC-MS/MS" Poster Session 885 Wednesday, November
19, 2008 1:00 p.m. - 5:00 p.m. EST -- "Camk2(alpha) Heterozygous
knock-out mice: a model of bipolar disorder-related mania" Poster
Session 157 Sunday, November 16, 2008 8:00 a.m. - 12:00 p.m. EST --
"Age and task dependent alterations in cognitive performance exist
in the rTg4510 mouse model of human tauopathy" Poster Session 439
Monday, November 17, 2008 1:00 p.m. - 5:00 p.m. EST -- "Behavioral
characterization of rTg4510 tau transgenic mice" Poster Session 439
Monday, November 17, 2008 1:00 p.m. - 5:00 p.m. EST About the
Company Memory Pharmaceuticals Corp., a biopharmaceutical company,
is focused on developing innovative drugs for the treatment of
debilitating CNS disorders, many of which exhibit significant
impairment of memory and other cognitive functions, including
Alzheimer's disease and schizophrenia. For additional information,
please visit our website at http://www.memorypharma.com/. Safe
Harbor Statement This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks and uncertainties. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or Memory
Pharmaceuticals' prospects, future financial position, future
revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially
from projections or estimates due to a variety of important
factors, including the outcome of clinical trials of Memory
Pharmaceuticals' drug candidates and whether they demonstrate these
candidates' safety and effectiveness; the risks and uncertainties
associated with: obtaining additional financing to support Memory
Pharmaceuticals' R&D and clinical activities and operations;
obtaining regulatory approvals to conduct clinical trials and to
commercialize Memory Pharmaceuticals' drug candidates; Memory
Pharmaceuticals' ability to enter into and maintain collaborations
with third parties for its drug development programs; Memory
Pharmaceuticals' dependence on its collaborations and its license
relationships; achieving milestones under Memory Pharmaceuticals'
collaborations; Memory Pharmaceuticals' dependence on preclinical
and clinical investigators, preclinical and clinical research
organizations, manufacturers and consultants; protecting the
intellectual property developed by or licensed to Memory
Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain
listing on the Nasdaq Capital Market. These and other risks are
described in greater detail in Memory Pharmaceuticals' filings with
the Securities and Exchange Commission. Memory Pharmaceuticals may
not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Memory Pharmaceuticals disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this press
release. DATASOURCE: Memory Pharmaceuticals Corp. CONTACT: Jzaneen
Lalani, General Counsel, +1-201-802-7249 Web Site:
http://www.memorypharma.com/
Copyright
Grafico Azioni Memory Pharmaceuticals Corp (MM) (NASDAQ:MEMY)
Storico
Da Lug 2024 a Lug 2024
Grafico Azioni Memory Pharmaceuticals Corp (MM) (NASDAQ:MEMY)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Memory Pharmaceuticals Corp (MM) (NASDAQ): 0 articoli recenti
Più Memory Pharmaceuticals (MM) Articoli Notizie